
<http://bio2rdf.org/drugbank:DB00002> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Cetuximab" ;
	<http://schema.org/description> "Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions." ;
	<http://schema.org/drugClass> "Antineoplastic Agents" ;
	<http://schema.org/url> "https://schemaorg.metadatacenter.org/drugbank/DB00002.html" ;
	<http://schema.org/administrationRoute> "intravenous" ;
	<http://schema.org/availableStrength> <http://bio2rdf.org/drugbank_resource:b624d8e3e20d2f4d741378e7638c4819> , <http://bio2rdf.org/drugbank_resource:b9f61619a00a6c02f73eb60c5107544e> ;
	<http://schema.org/clinicalPharmacology> "Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factorâ€“alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production." ;
	<http://schema.org/dosageForm> "Solution" ;
	<http://schema.org/legalStatus> "Approved" ;
	<http://schema.org/mechanismOfAction> "Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread." ;
	<http://schema.org/nonProprietaryName> "IMC-C225" , "Anti EGFR" ;
	<http://schema.org/identifier> "drugbank:DB00002" ;
	<http://schema.org/sameAs> <http://www.rxlist.com/cgi/generic3/erbitux.htm> , <http://www.drugs.com/cdi/cetuximab.html> , <http://www.drugbank.ca/drugs/DB00002> .

<http://bio2rdf.org/drugbank_resource:b624d8e3e20d2f4d741378e7638c4819> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "2 mg/mL Solution form with intravenous route" .

<http://bio2rdf.org/drugbank_resource:b9f61619a00a6c02f73eb60c5107544e> a <http://schema.org/DrugStrength> ;
	<http://schema.org/description> "2 mg Solution form with intravenous route" .
